✦ LIBER ✦

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma

✍ Scribed by Niels W.C.J. Van De Donk; Shulamit Wittebol; Monique C. Minnema; Henk M. Lokhorst

Book ID: 108676532
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 65 KB
Volume: 148
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07931.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide (Revlimid), in combination

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

✍ Gareth J. Morgan; Stephen A. Schey; Ping Wu; Muralikrishan Srikanth; Karen J. Ph 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB

The oral combination of thalidomide, cyc

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

✍ García-Sanz, R; González-Porras, J R; Hernández, J M; Polo-Zarzuela, M; Sureda, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 169 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Low-dose thalidomide in combination with

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

✍ Charalampia Kyriakou; Kirsty Thomson; Shirley D'Sa; Angela Flory; Judith Hanslip 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Lenalidomide alone or in combination wit

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

✍ Minnema, M C; van der Veer, M S; Aarts, T; Emmelot, M; Mutis, T; Lokhorst, H M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB